Compliance to Artesunate-Amodiaquine Therapy for Uncomplicated Malaria in Rural Ghana - Full Text View

Sponsors and Collaborators:	Kintampo Health Research Centre, Ghana London School of Hygiene and Tropical Medicine, United Kingdom
Information provided by:	Kintampo Health Research Centre, Ghana
ClinicalTrials.gov Identifier:	NCT00873938

Purpose

With a change in malaria treatment policy to use combination antimalaria therapy, it is envisaged that compliance to combination therapy would be less than that of monotherapy that was being used for case management in Ghana. This is especially so as amodiaquine is unpopular because of its side-effects and the combination therapy is not a single formulation (fixed dose). Compliance may further be enhanced by community supervision through home visits of combination antimalarial therapy in cases of uncomplicated malaria.

This study would assess compliance to Artesunate-Amodiaquine therapy. It would also assess the effect of compliance to artesunate-amodiaquine therapy on clinical and parasitological cure rates. This study targeting age groups above ten years, would complement a child artesunate -amodiaquine efficacy study being undertaken by the same investigators in children ten years and below at Kintampo District at the same time. The funding for the child study has been approved by the Gates Malaria Partnership. Findings from both studies, involving all age groups would be made available to the National Malaria Control Programme and other stakeholders as practical information that may be beneficial to implementing policy change process from antimalarial monotherapy to a combination therapy.

Condition
Malaria

MedlinePlus related topics: Malaria

Drug Information available for: Artesunate Amodiaquine

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cohort, Prospective

Further study details as provided by Kintampo Health Research Centre, Ghana:

Primary Outcome Measures:

The main outcome is compliance to artesunate-amodiaquine combination therapy [ Time Frame: Within first three days after diagnosis of malaria ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Reasons for non-compliance [ Time Frame: Within 28 days after diagnosis of malaria ] [ Designated as safety issue: No ]
Participants' perception and acceptance of supervision [ Time Frame: Within 28 days after diagnosis of malaria ] [ Designated as safety issue: No ]
Parasite clearance rates on day 14 and 28 [ Time Frame: Within 28 days after diagnosis of malaria ] [ Designated as safety issue: No ]

Enrollment:	411
Study Start Date:	October 2005
Study Completion Date:	September 2006
Primary Completion Date:	July 2006 (Final data collection date for primary outcome measure)

Groups/Cohorts
1-supervised
2 -unsupervised

Detailed Description:

Primary objective:

To determine compliance to artesunate-amodiaquine therapy among patients diagnosed with acute uncomplicated malaria in the Kintampo District Hospital.

Secondary objectives:

To determine patients compliance to each of the two drugs (artesunate or amodiaquine )
To determine reasons for differential compliance to either of the two drugs (artesunate or amodiaquine).
To determine patients perception and acceptance of artesunate-amodiaquine therapy for acute uncomplicated malaria.
To determine the effect of compliance of artesunate-amodiaquine therapy on clinical and parasitological improvement in acute uncomplicated malaria.

Study design: The study will be a pragmatic randomized control trial. Patients will be recruited based on an inclusion criteria stated below. Baseline clinical symptoms of malaria and presence of malaria parasite (Plasmodium falciparum) in the blood of eligible patients reporting sick at the health facility would be determined. Study patients would be randomized into one of two groups, intervention and control groups.

Intervention:

The intervention refers to supervisory home visits by a trained community volunteer to ensure that paticipants comply to treatment during the artesunate-amodiaquine therapy. Supervisory home visits by a trained community volunteer form a major component of the Community Health Planning and Services programme being implemented by the Ghana Health Service. The intervention group would be supervised during artesunate-amodiaquine therapy and the control group would not be supervised during artesunate-amodiaquine therapy. The primary and secondary outcome measures below will be determined and compared among the intervention and control group

Primary outcome measure:

The main outcome is compliance to artesunate-amodiaquine combination therapy. It is defined as no artesunate or amodiaquine left on the fourth day after start of treatment of a malaria episode. This would be assessed by the investigators direct observation of the blister package of artesunate-Amodiaquine tablets.

Secondary outcome measures:

Reasons for non-compliance would be determined by response of study participants. Care-takers of children below 18 years will answer on behalf of their children with the child's assent.
Participants' perception and acceptance of supervision: It would be assessed by responses given by study participants in an indepth interview.
Parasite clearance rates on day 14 and 28 i.e. the proportion of study participants in each group with P. falciparum parasiteamia at day 14 and 28 determined by blood smear microscopy.
Clinical cure rates by days 14 and 28 i.e. the proportion of study participants in each group with symptoms of malaria on days 14 and 28 determined by a structured questionnaire at these times.

Eligibility

Ages Eligible for Study:	10 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

A rural population in the middle belt of Ghana

Criteria

Inclusion criteria:

Male and female patients aged above ten years reporting at the Kintampo district hospital.
Diagnosed as having Plasmodium falciparum uncomplicated malaria.
Axillary temperature ≥37.5oC but less than 40 oC or history of fever in preceding 24 hr.
Ability to tolerate oral therapy.
Patient who live and can be located in the Kintampo District.
Consent of patient and/or care giver (in the case of children)

Exclusion criteria:

Pregnant women.
Children ten years and below (to be catered for in the child antimalarial efficacy studies mentioned above).

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00873938

Locations

Ghana, Kintampo
Kintampo Health Research Centre
Brong Ahafo Region, Kintampo, Ghana

Sponsors and Collaborators

Kintampo Health Research Centre, Ghana

London School of Hygiene and Tropical Medicine, United Kingdom

Investigators

Principal Investigator:	Seth Owusu-Agyei, PhD	Kintampo Health Research Centre, Ghana
Principal Investigator:	Kwaku P Asante, MD, MPH	Kintampo Health Research Centre, Ghana

More Information

Additional Information:

Institutional Website, Kintampo Health Research Centre This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Kintampo Health Research Centre ( Kwaku Poku Asante )
Study ID Numbers:	2004/GD/70
Study First Received:	March 31, 2009
Last Updated:	April 1, 2009
ClinicalTrials.gov Identifier:	NCT00873938 History of Changes
Health Authority:	Ghana: Ghana-Netherlands Health Research Programme (Sponsors); Ghana: Ghana Health Service Ethical Review Committee

Keywords provided by Kintampo Health Research Centre, Ghana:

Artesunate-Amodiaquine
Compliance
Malaria

Study placed in the following topic categories:

Artesunate
Protozoan Infections
Amodiaquine
Parasitic Diseases
Malaria

Additional relevant MeSH terms:

Protozoan Infections
Coccidiosis
Parasitic Diseases
Malaria

ClinicalTrials.gov processed this record on May 07, 2009